BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
BD announced positive nine-month results from the AGILITY IDE trial's iliac cohort for the Revello Vascular Covered Stent, presented at VIVA 2026. The 120-patient cohort met its composite endpoint with a 2.8% failure rate versus a 19% performance goal, alongside 97.2% primary patency and 98.3% freedom from clinically driven revascularization, with no device- or procedure-related deaths or amputations.
Key figures
- Drug Name
- Revello Vascular Covered Stent
- Phase Of Trial
- IDE trial, 9-month follow-up of 36-month study
- Sites
- 28
- Cohort size
- 120
- Rutherford 9mo
- 0.3
- Primary patency
- 97.2%
- Performance goal
- 19%
- Freedom from cd tlr
- 98.3%
- Rutherford baseline
- 3
- Wiq improvement points
- 31.7
- Composite endpoint failure rate
- 2.8%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.